恒瑞医药(01276.HK)：注射用SHR-A2102等三款药物获临床试验批准

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trials of three drugs, indicating progress in its research and development pipeline [1] Group 1 - The company’s subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has been granted approval for the clinical trial of SHR-A2102 [1] - Shanghai Heng Rui Medicine Co., Ltd. has received approval for the clinical trial of Adalimumab injection [1] - Shanghai Shengdi Medicine Co., Ltd. has been authorized to conduct clinical trials for SHR-1802 [1]